Urine CXCL10 as a biomarker in kidney transplantation

Curr Opin Organ Transplant. 2024 Jan 22. doi: 10.1097/MOT.0000000000001135. Online ahead of print.ABSTRACTPURPOSE OF REVIEW: Urine CXCL10 is a promising biomarker for posttransplant renal allograft monitoring but is currently not widely used for clinical management.RECENT FINDINGS: Large retrospective studies and data from a prospective randomized trial as well as a prospective cohort study demonstrate that low urine CXCL10 levels are associated with a low risk of rejection and can exclude BK polyomavirus replication with high certainty. Urine CXCL10 can either be used as part of a multiparameter based risk assessment tool, or as an individual biomarker taking relevant confounders into account. A novel Luminex-based CXCL10 assay has been validated in a multicenter study, and proved to be robust, reproducible, and accurate.SUMMARY: Urine CXCL10 is a well characterized inflammation biomarker, which can be used to guide performance of surveillance biopsies. Wide implementation into clinical practice depends on the availability of inexpensive, thoroughly validated assays with approval from regulatory authorities.PMID:38235748 | DOI:10.1097/MOT.0000000000001135
Source: Current Opinion in Organ Transplantation - Category: Transplant Surgery Authors: Source Type: research